GIP/GLP-1/Glucagon Triple Receptor Agonist
Retatrutide
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor agonism to the dual GIP/GLP-1 mechanism is hypothesized to further enhance energy expenditure and hepatic fat reduction. Early clinical research has shown substantial weight loss and metabolic improvements, making it a significant research tool in obesity and metabolic disease models.
Research Benefits
Key Research Applications
Documented areas of investigation based on peer-reviewed preclinical and clinical literature. For research reference only.
Glucose Regulation
Modulates glucose-dependent insulin secretion and glycemic control pathways.
Energy Expenditure
Studied for effects on metabolic rate and energy homeostasis in preclinical models.
Body Weight Modulation
Investigated for appetite signaling and adipose tissue regulation mechanisms.
Cardiometabolic Health
Research has explored effects on lipid profiles, blood pressure, and cardiovascular markers.
Literature
Research Highlights
Up to 24.2% body weight reduction in Phase 2 TRIUMPH trial (Jastreboff et al., 2023)
Triple receptor engagement enhances energy expenditure beyond dual agonists
Significant hepatic fat reduction observed in NAFLD research models
Improved cardiometabolic markers including triglycerides and blood pressure
Specifications
Technical Data
Molecular Weight
4973.61 g/mol
Sequence / Structure
Triple receptor agonist peptide — proprietary sequence analog
Storage Conditions
Lyophilized: −20°C, stable 24 months. Reconstituted: 4°C, use within 28 days.
Solubility
Soluble in 10mM PBS pH 7.4 at ≥1 mg/mL
HPLC Purity
Verified — Batch VRC-RET-2406
Testing Lab
Eurofins Scientific · Jun 2026
Research Areas
Ready to Order Retatrutide?
Retatrutide is currently in stock. View pricing, sizes, and the full Certificate of Analysis on the product page.
For Research Purposes Only. Retatrutide is sold exclusively for in vitro laboratory research. Not for human consumption, diagnostic, therapeutic, or veterinary use. Research highlights are summaries of published preclinical and clinical studies and do not constitute medical advice or claims of efficacy. See our Research Use Disclaimer.